| Humira (adalimumab) / AbbVie |
NCT00224562: The RATIO: Registry of Infections and Lymphoma in Patients Treated With TNF-a Antagonists |
|
|
| Unknown status | N/A | | Europe | TNF-alpha antagonists | Assistance Publique - Hôpitaux de Paris | Rheumatoid Arthritis, Crohn's Disease, Ankylosing Spondylitis, Psoriasis | | | | |
|
| Completed | N/A | 8 | Europe | adalimumab | University Hospital, Tours | Rheumatoid Arthritis | 12/07 | 12/08 | | |
PROWD, NCT00650390: Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab |
|
|
| Approved for marketing | N/A | | Europe | adalimumab, ABT-D2E7, Humira | Abbott | Rheumatoid Arthritis | | | | |
CanAct, NCT00649545: Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis |
|
|
| Approved for marketing | N/A | | Canada | adalimumab, ABT-D2E7, Humira | Abbott | Rheumatoid Arthritis | | | | |
ReAct, NCT00650026: Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis |
|
|
| Approved for marketing | N/A | | RoW | adalimumab, ABT-D2E7, Humira | Abbott | Rheumatoid Arthritis | | | | |
| Unknown status | N/A | 100 | NA | sperm quality test | Tel-Aviv Sourasky Medical Center | Crohn's Disease, Ulcerative Colitis | | | | |
NCT00724672: A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521) |
|
|
| Withdrawn | N/A | 0 | Europe | etanercept, Enbrel®, infliximab, Remicade®, SCH 215596, adalimumab, Humira® | Merck Sharp & Dohme LLC | Rheumatoid Arthritis | 07/09 | 07/09 | | |
NCT01585064: Optimization of Treatment With Adalimumab (Humira) |
|
|
| Completed | N/A | 309 | Canada | DAS28-IOMS, 0SJ-IOMS, Routine Care (RC) | Lawson Health Research Institute, Abbott | Rheumatoid Arthritis (RA) | 12/09 | 02/10 | | |
DALI, NCT01078571: Safety and Effectiveness of Adalimumab in Patients Diagnosed With Rheumatoid Arthritis |
|
|
| Completed | N/A | 705 | Europe | adalimumab (HUMIRA®), HUMIRA®, adalimumab | Abbott | Rheumatoid Arthritis | 05/10 | 05/10 | | |
HEOR, NCT01078116: Cost Utility Analyses of Adalimumab Treatment in Patients With Rheumatoid Arthritis (RA) |
|
|
| Completed | N/A | 124 | Europe | | Abbott, Institute of Political Economical & Social Researches, Greece | Rheumatoid Arthritis | 06/10 | 06/10 | | |
NCT01083693: Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs |
|
|
| Completed | N/A | 162 | Europe | | Abbott, Group Data Management Biostatistics | Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis | 06/10 | 06/10 | | |
NCT01144156: Small Bowel Mucosal Healing Induced by Adalimumab in Crohn's Disease Patients as Assessed by Capsule Endoscopy |
|
|
| Unknown status | N/A | 30 | RoW | Treatment with Adalimumab, Humira (Abbott Laboratories) | Rabin Medical Center, Abbott | Crohn's Disease | | | | |
| Completed | N/A | 3435 | Europe, RoW | adalimumab, HUMIRA® | Abbott | Rheumatoid Arthritis | 07/10 | 07/10 | | |
|
| Completed | N/A | 28 | Canada | Adalimumab, Humira | Université de Sherbrooke, Abbott | Rheumatoid Arthritis | 09/10 | 03/11 | | |
FALLA, NCT01083160: Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active Rheumatoid Arthritis (RA). A Multicenter Post-Marketing Observational Study in Routine Clinical Use |
|
|
| Terminated | N/A | 82 | RoW | | Abbott | Rheumatoid Arthritis | 11/10 | 11/10 | | |
NCT02376478: On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection |
|
|
| Completed | N/A | 222 | Europe | TNF-alpha inhibitors, Infliximab, adalimumab, etanercept, Alternative/no medication, fumaric acid, mesalazine, sulfasalazine, Purine/folic acid analogues, azathioprin, 6-mercaptopurine, methotrexate | Medical University of Vienna | Psoriasis, Inflammatory Bowel Diseases | 01/11 | 01/11 | | |
NCT02322008: Anti-TNF Therapy in Danish Patients With Inflammatory Bowel Diseases in Clinical Practice |
|
|
| Completed | N/A | 1035 | RoW | infliximab and adalimumab, remicade and humira, anti-TNF | Regionshospitalet Viborg, Skive | Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease | 03/11 | 03/11 | | |
NCT01084668: Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic Drugs |
|
|
| Completed | N/A | 46 | Europe | | Abbott, Assign Data Management and Biostatistics GmbH | Psoriasis Chronic | 04/11 | 04/11 | | |
NCT00638261: Primary UVB-311nm and Adalimumab in Psoriasis Patients |
|
|
| Completed | N/A | 4 | Europe | UVB-311nm, narrow-band UVB radiation | Medical University of Graz | Psoriasis | 08/11 | 08/11 | | |
NCT01012570: The Effect of Adalimumab on the Bone Microstructure in Crohn's Disease (CD) Patients |
|
|
| Terminated | N/A | 34 | Europe | Application of Adalimumab | Gerhard Rogler | Crohn's Disease | 08/11 | | | |
MAINTAIN, NCT01692899: Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice |
|
|
| Completed | N/A | 780 | Europe | | Pfizer, scientific steering committee of KOL in rheumatology | Rheumatoid Arthritis | 09/11 | 09/11 | | |
NCT01163916: Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care |
|
|
| Completed | N/A | 252 | RoW | | Abbott, Scientific Research Institute of Rheumatology, Moscow, Almedis | Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis | 11/11 | 11/11 | | |
EviraEAST, NCT01078402: EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries |
|
|
| Completed | N/A | 809 | Europe, RoW | | AbbVie (prior sponsor, Abbott) | Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA, Rheumatoid Arthritis (RA | 11/11 | 11/11 | | |
NCT01435265: Nurse Education in Subjects With Psoriasis Undergoing Treatment With Adalimumab |
|
|
| Completed | N/A | 7 | US | Standard nurse education, Additional nurse education | Wake Forest University Health Sciences | Psoriasis | 04/12 | 04/12 | | |
NCT01083121: Surveillance of Humira Injection in Korean Patients |
|
|
| Completed | N/A | 1779 | RoW | | AbbVie (prior sponsor, Abbott), Eisai Co., Ltd. | Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease, Psoriasis | 06/12 | 06/12 | | |
NCT00963313: A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis |
|
|
| Completed | N/A | 29 | Europe | Adalimumab (HUMIRA®), HUMIRA® | Dr. FRANCISCO J. BLANCO-GARCIA | Psoriatic Arthritis | 06/12 | 06/14 | | |
NCT01086033: A 3-year Study Following up Patients With Moderate to Severe Rheumatoid Arthritis Treated With Humira in Greece |
|
|
| Completed | N/A | 566 | Europe | | AbbVie (prior sponsor, Abbott) | Rheumatoid Arthritis | 07/12 | 07/12 | | |
NCT01155570: Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation) |
|
|
| Completed | N/A | 752 | Japan | | AbbVie (prior sponsor, Abbott) | Psoriasis | 07/12 | 07/12 | | |
|
|
ELAN, NCT01078610: Safety and Effectiveness and Effect on Quality of Life and Work Productivity of Humira in Patients With Psoriatic Arthritis in Clinical Routine |
|
|
| Withdrawn | N/A | 0 | Europe | adalimumab (Humira), adalimumab, Humira | Abbott | Psoriatic Arthritis | | | | |
NCT01077128: Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adalimumab |
|
|
| Completed | N/A | 500 | Europe | | AbbVie (prior sponsor, Abbott) | Psoriasis | 09/12 | 09/12 | | |
HOPE 3, NCT01163292: Special Investigation (Follow-up Survey of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859 (NCT00870467)) |
|
|
| Completed | N/A | 220 | Japan | | AbbVie (prior sponsor, Abbott) | Rheumatoid Arthritis | 10/12 | 10/12 | | |
|
NCT01436019: Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis |
|
|
| Unknown status | N/A | 100 | Europe | | Blood Transfusion Centre of Slovenia, University Medical Centre Ljubljana | Juvenile Idiopathic Arthritis | 10/12 | 12/12 | | |
| Completed | N/A | 48 | Europe | anti-TNF therapy (etanercept or adalimumab), Enbrel, Humira | Imperial College London | Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis | 12/12 | 12/12 | | |
NCT01464021: A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimumab in Patients With Moderately to Severely Active Rheumatoid Arthritis in China |
|
|
| Terminated | N/A | 26 | RoW | | AbbVie (prior sponsor, Abbott) | Arthritis, Rheumatoid | 12/12 | 12/12 | | |
| Unknown status | N/A | 2000 | Europe | Immunosuppressive Agents, Prednisolone, Azathioprine, Methotrexate, Mycophenolate mofetil, Cyclosporine A, Infliximab, Adalimumab, Etanercept, Rituximab | Royal Surrey County Hospital NHS Foundation Trust | Uveitis, Scleritis | 12/12 | 12/12 | | |
NCT01273519: Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to be Treated With Adalimumab |
|
|
| Completed | N/A | 155 | Europe | | AbbVie (prior sponsor, Abbott), Raffeiner GmbH | Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis | 01/13 | 01/13 | | |
NCT01077258: Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice |
|
|
| Completed | N/A | 4208 | Europe | | AbbVie (prior sponsor, Abbott) | Rheumatoid Arthritis | 02/13 | 02/13 | | |
NCT01298648: Special Investigation in Patients With Crohn's Disease (All Patients Investigation) |
|
|
| Completed | N/A | 1716 | Japan | | AbbVie (prior sponsor, Abbott) | Crohn's Disease | 02/13 | 02/13 | | |
NCT01078090: Effectiveness and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice |
|
|
| Completed | N/A | 5745 | Europe | | AbbVie (prior sponsor, Abbott) | Rheumatoid Arthritis | 03/13 | 03/13 | | |
NCT01387789: A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia |
|
|
| Completed | N/A | 71 | RoW | | AbbVie (prior sponsor, Abbott) | Rheumatoid Arthritis | 03/13 | 03/13 | | |
MB, NCT01105741: Metabolomic Analysis, a Potential Tool to Direct Treatment With Adalimumab in Crohn's Disease (CD) |
|
|
| Completed | N/A | 25 | Canada | | Martin Storr, Abbott | Crohn's Disease | 04/13 | 12/13 | | |
ADIBD, NCT01860963: Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls |
|
|
| Completed | N/A | 310 | US | Anal Pap smear and HPV DNA testing | Stanford University | Anal Squamous Intraepithelial Lesion (ASIL), HPV DNA | 06/13 | 06/13 | | |
NCT01029613 / 2009-014394-41: Adalimumab in Rheumatoid Arthritis. An Investigation of Wholebody MRI, Conventional MRI, CT and Circulating Biomarkers |
|
|
| Completed | N/A | 40 | Europe | Adalimumab | Glostrup University Hospital, Copenhagen | Rheumatoid Arthritis | 07/13 | 07/13 | | |
NCT01202565: Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice |
|
|
| Completed | N/A | 506 | Europe, RoW | | AbbVie (prior sponsor, Abbott) | Moderate to Severe Plaque Psoriasis | 07/13 | 07/13 | | |
NCT05759104: Treatment and Fate in Fistulizing Crohn's Disease in a Pediatric Population |
|
|
| Active, not recruiting | N/A | 40 | NA | Infliximab, Adalimumab, Ustékinumab, Stomy, Resection | Central Hospital, Nancy, France | Crohn Disease | 07/13 | 07/23 | | |
NCT01657513: TNF-alfa Inhibitors and Antibody Production in Patients With Psoriasis |
|
|
| Unknown status | N/A | 60 | Europe | subjects will receive either infliximab, adalimumab or etanercept, infliximab, adalimumab, etanercept | University Hospital, Gentofte, Copenhagen, The Michaelsen Foundation, Pfizer | Psoriasis | 07/13 | | | |
NCT01156532: Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy |
|
|
| Terminated | N/A | 30 | RoW | | AbbVie (prior sponsor, Abbott) | Moderate to Severe Psoriasis | 08/13 | 08/13 | | |
| Completed | N/A | 38 | Europe | Dovobet, neotigason, etanercept, adalimumab. infliximab | University of Aberdeen, NHS Grampian | Psoriasis | 09/13 | 09/13 | | |
NCT01428115: Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab |
|
|
| Completed | N/A | 83 | Europe | | AbbVie (prior sponsor, Abbott), Raffeiner GmbH | Severe Crohn's Disease, Anxiety | 10/13 | 10/13 | | |
NCT01111240: Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical Practice |
|
|
| Completed | N/A | 4635 | Europe | | AbbVie (prior sponsor, Abbott) | Psoriatic Arthritis | 12/13 | 12/13 | | |
| Completed | N/A | 21 | Europe | Adalimumab and Infliximab | University Hospital, Ghent, Abbott | Crohn's Disease | 02/14 | 02/14 | | |
NCT01316224: Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment |
|
|
| Completed | N/A | 52 | RoW | | AbbVie (prior sponsor, Abbott) | Psoriasis, Psoriatic Arthritis | 04/14 | 04/14 | | |
NCT02147600: Therapeutic Drug Monitoring of Adalimumab in Psoriasis Patients |
|
|
| Completed | N/A | 82 | Europe | | University Hospital, Ghent | Psoriasis | 04/14 | 04/14 | | |
NCT01079182: Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondylitis (AS) |
|
|
| Completed | N/A | 4681 | NA | | AbbVie (prior sponsor, Abbott) | Ankylosing Spondylitis | 05/14 | 05/14 | | |
NCT01078155: Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid Arthritis |
|
|
| Completed | N/A | 131 | Europe, RoW | | AbbVie (prior sponsor, Abbott) | Rheumatoid Arthritis, Osteoporosis | 05/14 | 05/14 | | |
NCT01163318: Special Investigation of Humira® (Adalimumab) on Long-term Treatment in Patients With Rheumatoid Arthritis |
|
|
| Completed | N/A | 552 | Japan | | AbbVie (prior sponsor, Abbott) | Rheumatoid Arthritis | 05/14 | 05/14 | | |
NCT01328366: Quality of Life and Psychosocial Factors Associated With Severe Psoriasis Following Treatment With Adalimumab |
|
|
| Completed | N/A | 153 | Europe | | AbbVie (prior sponsor, Abbott), pH Associates | Psoriasis | 05/14 | 05/14 | | |
NCT01474876: Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis |
|
|
| Completed | N/A | 566 | Europe, RoW | | AbbVie (prior sponsor, Abbott) | Ankylosing Spondylitis, Psoriatic Arthritis | 05/14 | 05/14 | | |
NCT01759264: An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Moderate-to-severe Crohn's Disease on Adalimumab Induction Therapy: a KoRean Experience (FAIR) |
|
|
| Completed | N/A | 101 | RoW | | AbbVie (prior sponsor, Abbott) | Crohn's Disease | 05/14 | 05/14 | | |
NCT01812954: Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis |
|
|
| Completed | N/A | 1 | NA | Methotrexate, Cyclosporins, fumaric acid, Acitretin, Infliximab, etanercept, Adalimumab, Ustekinumab | Jochen Schmitt., Merck Sharp & Dohme LLC | Psoriasis | 06/14 | 06/14 | | |
NCT01881464: Anti TNF α Improves Endothelial Dysfunction in IBD Patients |
|
|
| Unknown status | N/A | 20 | RoW | Endopath from Itamar medical - FDA approved device., Anti TNF Alfa., HUMIRA-ADALIMUMAB, REMICADE-INFLIXIMAB | Carmel Medical Center | Crohn's Disease | 06/14 | 06/18 | | |
NCT01282372: Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab |
|
|
| Completed | N/A | 500 | NA | | AbbVie (prior sponsor, Abbott) | Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis | 07/14 | 07/14 | | |
NCT01782469: Rheumatoid Arthritis Patients on Adalimumab to Evaluate Its Effect on Synovitis Using Ultrasonography in an Egyptian Population |
|
|
| Terminated | N/A | 16 | RoW | | AbbVie (prior sponsor, Abbott) | Rheumatoid Arthritis | 07/14 | 07/14 | | |
PROMISE, NCT01076192: Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain |
|
|
| Completed | N/A | 547 | Europe | | AbbVie (prior sponsor, Abbott), IMS Health | Moderate-to-severe Chronic Plaque Psoriasis | 09/14 | 09/14 | | |
NCT01346501: Special Investigation in Patients With Rheumatoid Arthritis (HOPEFUL III Study), a Follow-up Survey of Study P12-069 |
|
|
| Completed | N/A | 172 | Japan | | AbbVie (prior sponsor, Abbott) | Rheumatoid Arthritis | 11/14 | 11/14 | | |
| Completed | N/A | 1013 | Canada | | AbbVie (prior sponsor, Abbott), University Health Network, Toronto | Moderate-to-severe Rheumatoid Arthritis | 12/14 | 12/14 | | |
NCT00638469: UVB-311nm After Initial Slow Response to Adalimumab in Psoriasis |
|
|
| Unknown status | N/A | 10 | Europe | UVB-311nm, narrow-band UVB radiation, No treatment | Medical University of Graz | Psoriasis | 12/14 | 12/14 | | |
ANTIBODY-RA, NCT01981473: Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab |
|
|
| Completed | N/A | 605 | US, Europe, RoW | no intervention, Enbrel, Humira, Remicade | Pfizer | Rheumatoid Arthritis | 12/14 | 12/14 | | |
NCT01169987: Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life |
|
|
| Completed | N/A | 191 | Europe | | AbbVie (prior sponsor, Abbott), Veeda Clinical Research | Psoriasis | 03/15 | 03/15 | | |
NCT01320293: Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab. |
|
|
| Completed | N/A | 18 | US | Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA], Humira | University of North Carolina, Chapel Hill, AbbVie | Psoriasis | 03/15 | 03/15 | | |
NCT01901627: A Multicenter Registry of Adalimumab in Chinese Adult Patients With Active Ankylosing Spondylitis |
|
|
| Unknown status | N/A | 400 | RoW | | Peking Union Medical College Hospital | Spondylitis, Ankylosing | 06/15 | 06/15 | | |
NCT01356758: Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents |
|
|
| Completed | N/A | 126 | Europe | biological treatment, Adalimumab, Etanercept, Infliximab, Ustekinumab | University of Aarhus, Aarhus University Hospital, Aage Bangs Fond, AbbVie, Region Midt Forskningsfond | Psoriasis, Atopic Dermatitis, Atherosclerosis | 09/15 | 11/15 | | |
NCT01754727: Impact of Adalimumab (Humira®) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice |
|
|
| Completed | N/A | 452 | Europe, RoW | | AbbVie (prior sponsor, Abbott) | Ankylosing Spondylitis | 10/15 | 10/15 | | |
NCT01756235: Physical Activity in Patients With Rheumatoid Arthritis Treated With Adalimumab in Routine Clinical Practice |
|
|
| Completed | N/A | 462 | Europe, RoW | | AbbVie (prior sponsor, Abbott) | Rheumatoid Arthritis | 10/15 | 10/15 | | |
AdaProQuo, NCT02092389: Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - |
|
|
| Terminated | N/A | 10 | Europe | | AbbVie | Moderate to Severe Ulcerative Colitis | 10/15 | 03/16 | | |
| Active, not recruiting | N/A | 210 | Europe | | Helse Stavanger HF, Rikshospitalet University Hospital, Oslo University Hospital | Inflammatory Bowel Disease | 11/15 | 12/24 | | |
PYRAMID, NCT00524537: A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD) |
|
|
| Completed | N/A | 5025 | NA | | AbbVie (prior sponsor, Abbott) | Crohn's Disease | 12/15 | 12/15 | | |
|
|
|
NCT01346488: Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment) |
|
|
| Completed | N/A | 2088 | NA | | AbbVie (prior sponsor, Abbott) | Rheumatoid Arthritis | 01/16 | 01/16 | | |
ULSPABIT, NCT01219257: Longitudinal ULtrasonographic Study of Patients With Spondylarthritis Starting Biological Therapy |
|
|
| Completed | N/A | 50 | Europe | Anti-TNF alpha therapy, Adalimumab (HumiraR), Etanercept (EnbrelR), Infliximab (RemicadeR), Golimumab (SimponiR) | Diakonhjemmet Hospital | Spondyloarthritis, Ultrasonography | 01/16 | 01/16 | | |
ENHANCE, NCT02676817: Confocal Laser Endomicroscopy for Assessment of Mucosal Healing in Ulcerative Colitis |
|
|
| Unknown status | N/A | 100 | Europe | | European Georges Pompidou Hospital | Colitis, Ulcerative | 02/16 | 02/17 | | |
| Unknown status | N/A | 180 | Europe | All types of surgery procedures, Simple seton drain removal | French Society of Coloproctology | Crohn Disease, Fistula, Anoperineal Fistula, Anal Fistula | 03/16 | 03/17 | | |
PASSION, NCT01383421: Observational Study to Explore the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP) |
|
|
| Completed | N/A | 1036 | NA | | AbbVie (prior sponsor, Abbott) | Rheumatoid Arthritis | 04/16 | 04/16 | | |
ABI-RA, NCT02116504: Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients |
|
|
| Unknown status | N/A | 156 | Europe | Sampling of blood | Assistance Publique - Hôpitaux de Paris, Institut National de la Santé Et de la Recherche Médicale, France, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Leiden University Medical Center, University College London (UCL) Cancer Institute, University of Florence, Pediatric Rheumatology International Trials Organization, Istituto Giannina Gaslini, GlaxoSmithKline, University Hospital, Tours | Rheumatoid Arthritis, Juvenile Idiopathic Arthritis | 04/16 | 11/17 | | |
| Completed | N/A | 28 | RoW | | AbbVie | Polyarticular Juvenile Idiopathic Arthritis | 04/16 | 04/16 | | |
NCT02434133: Cross Sectional Study of Vaccine Antibody Response in Inflammatory Bowel Disease Patients |
|
|
| Completed | N/A | 110 | US | Blood Draw/Data Collection | University of Wisconsin, Madison | Inflammatory Bowel Disease (IBD) | 04/16 | 12/17 | | |
NCT01401452: Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities |
|
|
| Completed | N/A | 246 | NA | | AbbVie (prior sponsor, Abbott), Raffeiner GmbH | Moderate to Severe Plaque Psoriasis | 05/16 | 05/16 | | |
NCT02073526: Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease |
|
|
| Completed | N/A | 1230 | Europe | Infliximab, adalimumab, certolizumab pegol | Oslo University Hospital | Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis | 05/16 | 11/16 | | |
NCT02450513: Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study |
|
|
| Completed | N/A | 30 | Europe | Adalimumab, Humira | Universitaire Ziekenhuizen KU Leuven | Crohn's Disease | 05/16 | 05/16 | | |
| Completed | N/A | 944 | US | | University of California, San Diego, The Organization of Teratology Information Specialists, Abbott | Crohn's Disease, Rheumatoid Arthritis | 08/16 | 10/19 | | |
NCT01971970: Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD) |
|
|
| Completed | N/A | 45 | Europe | Infliximab, Remicade, Adalimumab, Humira | Erasmus Medical Center, Merck Sharp & Dohme LLC | Inflammatory Bowel Diseases | 10/16 | 01/17 | | |
| Completed | N/A | 70 | Europe | adalimumab, ATC code L04AB04, CAS 331731-18-1, Placebo, Placebo, no other name | Karolinska Institutet, Abbott, Swedish Foundation for Strategic Research, The Swedish Research Council | Arthritis, Rheumatoid, Pain, Fatigue | 11/16 | 11/16 | | |
NCT02330380: Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation |
|
|
| Completed | N/A | 26 | US | Methotrexate, Ustekinumab, Etanercept, Adalimumab, Acitretin, UVB Excimer Laser, Narrowband UVB | University Hospitals Cleveland Medical Center, National Psoriasis Foundation | Psoriasis, Inflammation | 12/16 | 12/16 | | |
CEDAR UC, NCT03142113: Clinical Outcome After Escalation and De-escalation of Adalimumab in Real Life in Ulcerative Colitis |
|
|
| Completed | N/A | 231 | Europe | | Universitaire Ziekenhuizen Leuven, Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW, Imelda Hospital, Bonheiden, University of Liege, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, AZ Delta, Algemeen Ziekenhuis Maria Middelares, University Hospital, Ghent, General Hospital Groeninge, Centre Hospitalier Universitaire Dinant Godinne - UCL Namur, Université Catholique de Louvain, Onze Lieve Vrouwziekenhuis Aalst | Ulcerative Colitis | 12/16 | 05/17 | | |
NCT02414633: Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity Impairment [WPAI]) |
|
|
| Completed | N/A | 148 | NA | | AbbVie | Psoriatic Arthritis | 03/17 | 03/17 | | |
NCT01960790: Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation) |
|
|
| Completed | N/A | 473 | NA | | AbbVie | Behcet's Disease | 05/17 | 05/17 | | |
| Completed | N/A | 60 | Europe | Anti-TNF Biologics Therapy, Etanercept (Enbrel), Adalimumab (Humira), Certolizumab Pegol(Cimzia) | Queen Mary University of London | Rheumatoid Arthritis | 05/17 | 05/17 | | |
NCT02578238: Post-Marketing Surveillance of Humira in Korean Pediatric Crohn's Disease (CD) Patients Under the "New-Drug Re-examination" |
|
|
| Completed | N/A | 143 | NA | | AbbVie | Pediatric Crohn's Disease | 05/17 | 05/17 | | |
SPACTIVE, NCT01845818: Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium |
|
|
| Completed | N/A | 183 | NA | | AbbVie | Ankylosing Spondylitis, Psoriatic Arthritis | 06/17 | 06/17 | | |
PUCCINI, NCT02054533: Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease |
|
|
| Completed | N/A | 974 | US | | Icahn School of Medicine at Mount Sinai | Crohn's Disease, Ulcerative Colitis | 06/17 | 06/17 | | |
AS PMOS, NCT02333383: Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients |
|
|
| Completed | N/A | 201 | NA | Adalimumab, Humira, ABT-D2E7 | AbbVie | Ankylosing Spondylitis | 08/17 | 08/17 | | |
